News
- Author:
- Patrice Wendling
Publish date: August 22, 2014
Key clinical point: Rates of malignancy were higher among patients with psoriasis than in the general population.
Major finding: The 5-year malign...
News
- Author:
- Patrice Wendling
Publish date: August 22, 2014
News
- Author:
- Patrice Wendling
Publish date: August 22, 2014
News
- Author:
- Patrice Wendling
Publish date: August 20, 2014
Key clinical point: Complete protection from Marburg virus–Angola hemorrhagic fever can be achieved in nonhuman primates, even when the trea...
News
- Author:
- Patrice Wendling
Publish date: August 13, 2014
Key clinical point: The risk of being hospitalized for an infectious event was higher with exposure to infliximab.Major finding: The incidence of ...
News
- Author:
- Patrice Wendling
Publish date: August 11, 2014
Key clinical point: Thoracic radiotherapy may improve survival when delivered after chemotherapy in extensive-stage lung cancer responding to chem...
News
- Author:
- Patrice Wendling
Publish date: August 11, 2014
Key clinical point: Adjuvant EGFR TKI therapy may delay disease progression in NSCLC patients harboring an EGFR mutation.Major finding: Median DFS...
News
- Author:
- Patrice Wendling
Publish date: August 11, 2014
Key clinical point: The MelaFind device may be helpful to dermatologists when deciding which clinically ambiguous lesions may be early melanoma.
M...
News
- Author:
- Patrice Wendling
Publish date: July 21, 2014
Key clinical point: Long-time TKI therapy can be stopped in chronic myeloid leukemia in deep molecular remission.
News
- Author:
- Patrice Wendling
Publish date: July 21, 2014
Key clinical point: Long-time TKI therapy can be stopped in chronic myeloid leukemia in deep molecular remission.
News
- Author:
- Patrice Wendling
Publish date: July 21, 2014
Key clinical point: A significant proportion of NAFLD-related HCC patients have no cirrhosis at presentation, so clinicians need to maintain a hig...
News
- Author:
- Patrice Wendling
Publish date: July 21, 2014
Key clinical point: A significant proportion of NAFLD-related HCC patients have no cirrhosis at presentation, so clinicians need to maintain a hig...
News
- Author:
- Patrice Wendling
Publish date: July 21, 2014
Major finding: The overall response rate was 77% with ABT-199 monotherapy and 84% with the addition of rituximab in relapsed or refractory CLL.
Ke...
News
- Author:
- Patrice Wendling
Publish date: July 14, 2014
Key clinical point: Median progression-free survival with the classic chemotherapy doublets ranged from 4.5 months to 5.3 months but reached 6.75 ...
News
- Author:
- Patrice Wendling
Publish date: July 14, 2014
Key clinical point: ONO-4059 induced responses in most patients with relapsed/refractory CLL, including those with a 17p deletion.
Major finding: ...
